Potential therapeutic targets for Membranous Nephropathy: proteome-wide Mendelian randomization and colocalization analysis

Abstract

Background The currently available medications for treating membranous nephropathy (MN) still have unsatisfactory efficacy in inhibiting disease recurrence, slowing down its progression, and even halting the development of end-stage renal disease. There is still a need to develop novel drugs targeting MN.